PVR and cancer: In contrast, patients expressing CD155 were more likely to exhibit a poor chemotherapy response, as indicated by higher MD Anderson Cancer Center Residual Cancer Burden Index scores and Class II/III, compared to those without CD155 expression (100% vs 82.6%, p = 0.03; Table 2).